Credit Suisse Group Lowers Encompass Health (NYSE:EHC) Price Target to $62.00
Credit Suisse Group Lowers Encompass Health (NYSE:EHC) Price Target to $62.00
Encompass Health (NYSE:EHC – Get Rating) had its price target lowered by investment analysts at Credit Suisse Group from $63.00 to $62.00 in a research note issued to investors on Wednesday, MarketBeat reports. The firm presently has an "outperform" rating on the stock. Credit Suisse Group's target price would indicate a potential upside of 28.98% from the company's previous close.
據MarketBeat報道,在週三發佈給投資者的一份研究報告中,瑞士信貸集團的投資分析師將Entainass Health(紐約證券交易所代碼:EHC-GET評級)的目標價從63.00美元下調至62.00美元。該公司目前對該股的評級為“跑贏大盤”。瑞士信貸集團的目標價表明,該公司較前一交易日收盤價有28.98%的潛在上行空間。
Other research analysts have also issued reports about the company. Royal Bank of Canada dropped their price target on Encompass Health from $82.00 to $66.00 in a research report on Wednesday, August 24th. Truist Financial dropped their target price on Encompass Health from $75.00 to $65.00 and set a "buy" rating on the stock in a research report on Monday, August 8th. BMO Capital Markets dropped their target price on Encompass Health from $83.00 to $65.00 and set an "outperform" rating on the stock in a research report on Thursday, August 4th. Barclays dropped their target price on Encompass Health from $80.00 to $63.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Encompass Health from $80.00 to $62.00 in a research report on Wednesday, August 3rd. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $70.00.
其他研究分析師也發佈了關於該公司的報告。在8月24日星期三的一份研究報告中,加拿大皇家銀行將其對Enneass Health的目標價從82.0美元下調至66.00美元。Truist Financial在8月8日星期一的一份研究報告中將其對Enneass Health的目標價從75.00美元下調至65.00美元,並對該股設定了“買入”評級。BMO Capital Markets在8月4日(星期四)的一份研究報告中將Enneass Health的目標價從83.00美元下調至65.00美元,並對該股設定了“跑贏大盤”的評級。8月4日,巴克萊銀行在一份研究報告中將其目標價從80.00美元下調至63.00美元,並將該股的評級定為“增持”。最後,德意志銀行Aktiengesellschaft在8月3日星期三的一份研究報告中將Enneass Health的目標價從80.00美元下調至62.00美元。一名分析師對該股的評級為持有,8名分析師給出了買入評級,一名分析師對該股發出了強烈的買入評級。根據MarketBeat.com的數據,該股目前的共識評級為買入,共識目標價為70.00美元。
Encompass Health Stock Down 1.6 %
包括健康類股下跌1.6%
NYSE:EHC opened at $48.07 on Wednesday. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 2.37 and a beta of 1.02. Encompass Health has a 1-year low of $44.33 and a 1-year high of $78.31. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 1.29. The business's fifty day moving average price is $50.78 and its 200 day moving average price is $59.17.
紐約證交所:EHC週三開盤報48.07美元。該公司的市值為48億美元,市盈率為14.70倍,聚乙二醇率為2.37倍,貝塔係數為1.02。Engrass Health的一年低點為44.33美元,一年高位為78.31美元。該公司的流動比率為1.24,速動比率為1.24,債務權益比率為1.29。該業務的50日移動均線價格為50.78美元,200日移動均線價格為59.17美元。
Insider Activity
內幕活動
In related news, CEO Mark J. Tarr sold 20,449 shares of the stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $53.25, for a total transaction of $1,088,909.25. Following the completion of the sale, the chief executive officer now owns 440,895 shares in the company, valued at approximately $23,477,658.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.70% of the stock is currently owned by insiders.
在相關新聞中,首席執行官馬克·J·塔爾在8月17日星期三的一筆交易中出售了20,449股該公司股票。該股以53.25美元的平均價格出售,總成交金額為1088,909.25美元。出售完成後,首席執行官現在擁有該公司440,895股,價值約23,477,658.75美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站。目前該公司2.70%的股份由內部人士持有。
Institutional Trading of Encompass Health
Enneass Health的制度性交易
Several hedge funds have recently added to or reduced their stakes in EHC. Baupost Group LLC MA boosted its stake in Encompass Health by 318.9% during the 1st quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company's stock valued at $213,330,000 after purchasing an additional 2,283,900 shares during the period. Empyrean Capital Partners LP bought a new stake in Encompass Health during the 1st quarter valued at approximately $81,506,000. Massachusetts Financial Services Co. MA lifted its position in shares of Encompass Health by 88.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,685,880 shares of the company's stock worth $94,494,000 after acquiring an additional 792,813 shares during the period. Paradice Investment Management LLC bought a new stake in shares of Encompass Health in the 1st quarter worth approximately $47,388,000. Finally, Victory Capital Management Inc. lifted its position in shares of Encompass Health by 40.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,146,910 shares of the company's stock worth $120,335,000 after acquiring an additional 613,547 shares during the period. Institutional investors own 93.07% of the company's stock.
幾家對衝基金最近增持或減持了EHC的股份。Baupost Group LLC MA在第一季度將其在Enneass Health的持股增加了318.9%。Baupost Group LLC MA現在擁有300萬股該公司的股票,價值213,330,000美元,在此期間又購買了2,283,900股。Emyrean Capital Partners LP在第一季度購買了Enneass Health的新股份,價值約81,506,000美元。馬雲在第二季度將其在Enneass Health股票中的持倉提高了88.8%。馬雲在此期間增持了792,813股馬雲股票,目前持有1,685,880股該公司股票,價值94,494,000美元。Paradice Investment Management LLC在第一季度購買了Enneass Health的新股份,價值約47,388,000美元。最後,勝利資本管理公司在第二季度將其在Enneass Health的持股比例提高了40.0%。勝利資本管理公司在此期間增持了613,547股,目前持有該公司2,146,910股股票,價值120,335,000美元。機構投資者持有該公司93.07%的股票。
Encompass Health Company Profile
包含健康公司簡介
(Get Rating)
(獲取評級)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Enneass Health Corporation在美國提供基於設施和以家庭為基礎的急性後保健服務。該公司在兩個領域開展業務,住院康復以及家庭健康和臨終關懷。住院康復部分為正在康復的患者提供住院和門診的專門康復治療,這些疾病包括中風和其他神經疾病、心臟和肺部疾病、腦和脊髓損傷、複雜的骨科疾病和截肢。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免費獲取StockNews.com關於Enfass Health(EHC)的研究報告
- 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎?
- 這些機構持有達頓餐飲國際公司的股份
- 住房建設的黃金時代已經結束了嗎?
- 這三大股利支付者也擁有強勁的價格增長
- 天然氣價格繼續回升,這些股票應該會受益
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受《包羅萬象健康日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對Enneass Health及相關公司評級的每日簡要摘要。